
Personalis Inc (PSNL) Stock Forecast & Price Target
Personalis Inc (PSNL) Analyst Ratings
Bulls say
Personalis Inc has experienced a significant positive shift following the announcement of Medicare coverage for its proprietary NeXT Personal MRD test, leading to a notable 28% increase in stock value, which reflects strong market confidence in its offerings. The company's strategic decision to ease volume growth in Q3 to manage cash burn while awaiting reimbursement indicates a prudent financial approach that prioritizes long-term profitability. Additionally, expectations of accelerated marketing efforts by its commercial partner Tempus, combined with promising sales forecasts for its product line, support a bullish outlook on the company's future financial performance and market positioning.
Bears say
Personalis Inc. has faced challenges in meeting its revenue expectations due to a general slowdown in the biopharma industry and logistical issues affecting sample flow for minimal residual disease (MRD) testing, leading to a downward revision of its 2025 revenue guidance from $70-$80 million to $68-$73 million. The company's projected decline in revenue from biopharma services, specifically a $3 million reduction at the midpoint, coupled with significant losses incurred since inception and existing debt, raises concerns about its ability to achieve profitability in the near future. Additionally, the expected decrease in reimbursement for clinical sample testing further exacerbates the risks surrounding Personalis's financial outlook.
This aggregate rating is based on analysts' research of Personalis Inc and is not a guaranteed prediction by Public.com or investment advice.
Personalis Inc (PSNL) Analyst Forecast & Price Prediction
Start investing in Personalis Inc (PSNL)
Order type
Buy in
Order amount
Est. shares
0 shares